Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin analog presented as an ophthalmic solution for ophthalmic use. It lowers intra‑ocular pressure by increasing uveoscleral outflow of aqueous humor and is indicated for the treatment of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Monopost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Elevated intra‑ocular pressure: helps maintain target pressure and protect optic nerve health.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Eye irritation or foreign‑body sensation - Increased eyelash growth - Darkening of the iris color - Blurred vision - Mild eye discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., anaphylaxis) - Uveitis or intra‑ocular inflammation - Macular edema leading to vision changes - Persistent eye pain or photophobia - Sudden loss of vision - Pronounced iris pigmentation changes

Before initiating therapy, certain precautions should be considered.

Monitor intra‑ocular pressure: regular measurements are required to assess efficacy. Assess for ocular inflammation: avoid use in active uveitis or severe ocular infection. Caution in corneal disease: may exacerbate existing corneal conditions. Avoid concurrent prostaglandin analogs: risk of additive ocular side effects. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: may increase ocular side effects. - Combined use with systemic carbonic anhydrase inhibitors: additive IOP lowering may cause hypotony.

Moderate Interactions (Monitor Closely): - Use with beta‑blocker eye drops: monitor for excessive IOP reduction. - Use with systemic antihistamines: may reduce ocular surface tolerance. - Use with contact lens wear: may cause lens discoloration or discomfort.